Vaccination certificate for trial participants to be issued via Co-WIN

People who participated in Covid-19 vaccine trials will be issued digital certificates through the Co-WIN portal, the Union health ministry said on Monday.

coronavirus, covid
Coronavirus vaccine. Photo: PTI
Press Trust of India New Delhi
2 min read Last Updated : Aug 23 2021 | 7:52 PM IST

People who participated in COVID-19 vaccine trials will be issued digital certificates through the Co-WIN portal, the Union health ministry said on Monday.

In a statement, the ministry said it received several requests from trial participants for issuing certificates through Co-WIN.

"In a welcome initiative, digital #COVID19 vaccination certificates will now be issued to the clinical trial participants of COVISHIELD & COVAXIN through Co-WIN. The nation thanks them for their incredible commitment & contribution to COVID-19 vaccine research & treatment," Union Health Minister Mansukh Mandaviya tweeted.

"The participants can download their individual certificates through Co-WIN Portal, Aarogya Setu, Digilocker or the UMANG Application," he said.

The Indian Council of Medical Research (ICMR) in partnership with the Serum Institute of India (SII) had conducted phase II/III bridging studies of Covishield from August 2020. Phase III efficacy clinical trials for Covaxin were conducted by Bharat Biotech International Limited (BBIL) from November 2020.

The ministry said it was decided that vaccination certificates may be issued to such participants who were administered the vaccines during these trials after the trials were unblinded.

The ICMR was designated as the nodal agency for the collection of vaccination data for such participants by the ministry.

"The ICMR had provided the data for 11,349 such persons to the MoHFW. Digital vaccination certificates have now been issued through Co-WIN to such persons who participated in these studies/trials of Covishield and Covaxin," the statement said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: Aug 23 2021 | 7:39 PM IST

Next Story